Combating multidrug-resistant Helicobacter pylori with moenomycin A in combination with clarithromycin or metronidazole
Journal
Frontiers in chemistry
Journal Volume
10
Pages
897578
Date Issued
2022-10-19
Author(s)
Tseng, Yen-Yu
Cheng, Wei-Chieh
Hsu, Jing-Ting
Hsu, Tsui-Ling
Wong, Chi-Huey
Abstract
Current treatment of Helicobacter pylori involves a triple therapy comprising one proton pump inhibitor and two other antibiotics; however, the outcomes are limited due to the existence of antibiotic resistant strains. We previously reported that moenomycin A, a cell-wall transglycosylase inhibitor, is highly active against multidrug-resistant Helicobacter pylori. Herein we show that combination of moenomycin A with the protein synthesis inhibitor clarithromycin or metronidazole can synergistically achieve almost 95% eradication of multidrug-resistant Helicobacter pylori. We also found that the moenomycin A-non-susceptible strains of Helicobacter pylori with deletion of transglycosylase exhibit moenomycin A hyposensitivity, faster growth and impaired biofilm formation compared to the parental strain. Overall, the combination of moenomycin A and clarithromycin or metronidazole to achieve a synergistic effect on different targets is a promising treatment for multidrug-resistant Helicobacter pylori.
Subjects
helicobacter
antibiotics
combination
moenomycin
penicillin-binding protein knockout
SDGs
Publisher
FRONTIERS MEDIA SA
Type
journal article